Study of debrisoquine polymorphism in a sample of the Cuban population;Estudio del polimorfismo de debrisoquina en una muestra de la población cubana

Revista Cubana de Farmacia

Volumn 39, Issue 1, 2005, Pages

  Álvarez Corredera, Mayra ^a,b   Pérez Hernández, Bárbaro ^a   Llerena, Adrián ^a,c   Labacena Rodríguez, María ^a   García Bacallao, Lourdes ^a   Rojo Hernández, Delia ^a  

^a Facultad de Ciencias Medicas General Calixto Garcia   (Cuba)

^b Calle I No 260 Plaza de la Revolución ^*  (Cuba)

^c UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

CYP2D6; Debrisoquine polymorphism; Genetic polymorphism

Indexed keywords

EID: 55449120776     PISSN: 00347515     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ma K, Woo MH, Mcleod HL. Genetic Basis of Drug Metabolism. Am J Health-Syst Pharm. 2002;59(21):2061-9.
2. Wilkinson GR. Farmacocinética: dinámicas de absorción, distribución y eliminación de fármacos. En: Hardman JG, Limbird LE, Goodman A. Goodman and Gilman. Las bases farmacológicas de la terapéutica. 10 ed. México DF: McGraw-Hill Interamericana; 2003. p. 5-34.
3. Winn-Deen E. SNPs: Will human genetic variation lead to new medical practices? Lab Medica International. 2003;20(3):15-6.
4. El Manual Merck de diagnóstico y tratamiento. [Programa de ordenador]. Brees MH, Berkow R (eds). 10 ed. Madrid: Harcourt; 1999.
5. Kitada M. Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. Int J Clin Pharmacol Res. 2003;23(1):31-5.
6. Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol. 2003;17(1):27-41.
7. Kawanishi C, Lundgren S, Agren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. Eur J Clin Pharmacol. 2004;59(11):803-7.
8. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotschl R, Kopke K, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol. 2003;59(4):303-12.
9. Benítez J, Llerena A, Cobaleda J. Debrisoquin oxidation polymorphism in a Spanish population. Clin Pharmacol Ther. 1988;44:74-7.
10. Evans D, Magoub A, Sloan T, Idle J, Smith R. A family population study of the genetic polymorphism of debrisoquin oxidation in a white British population. J Med Genet. 1980;45:102-5.
11. Genetic differences in drug disposition. J Clin Pharmacol. 994;34:881-97.
12. Brockmoller J, Roots I. Assessment of liver metabolic function: clinical implications. Clin Pharmacokinet. 1994;27(3):216-48.
13. Estévez F, Giusty M, Parrillo S, Oxandabrat J. Dextromethorfan O-demethylation polymorphism in the Uruguayan population. Eur J Clin Pharmacol. 1997;52:417-8.
14. Llerena A, Cobaleda J, Martínez C, Benítez J. Interethnic differences in drug metabolism: influence of genetic and enviromental factors on debrisoquin hydroxylation phenotype. Eur J Drug Metab Pharmacokinet. 1996;21(2):129-38.
15. Mendoza R, Wan YJ, Poland RE, Smith M, Zheng Y, Berman N, et al. CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther. 2001;70(6):552-60.
16. Holgate ST. Pharmacogenetics: the new science of personalizing Treatment. Curr Opin Allergy Clin Immunol. 2004;4(1):37-8.